• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension

Publication
Article
Supplements and Featured PublicationsMeasuring Persistency with Drug Therapy in Glaucoma Management
Volume 8
Issue 10 Suppl

Download PDF: An Economic Analysis of Switching to Latanoprost from a Beta-Blocker or adding Brimonidine or Latanoprost to a Beta-Blocker in Open-Angle Glaucoma or Ocular Hypertension

© 2024 MJH Life Sciences
AJMC®
All rights reserved.